Stockscreener 앱 받기
0.00
100.00%
-4.36
전일 마감가:
$4.36
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$96.26M
수익:
-
순이익/손실:
$-94.11M
주가수익비율:
0.00
EPS:
-6.01
순현금흐름:
$-86.06M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$5.75
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
명칭
Adverum Biotechnologies Inc
전화
(650) 649-1004
주소
100 CARDINAL WAY, REDWOOD CITY, CA
Compare ADVM vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
0.00 | 96.26M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-30 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 업그레이드 | Truist | Hold → Buy |
| 2021-07-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | 다운그레이드 | Truist | Buy → Hold |
| 2020-12-16 | 개시 | UBS | Neutral |
| 2020-11-12 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-05-05 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-04-28 | 개시 | Goldman | Buy |
| 2020-03-16 | 개시 | SVB Leerink | Outperform |
| 2020-02-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | 재확인 | Chardan Capital Markets | Neutral |
| 2019-09-13 | 재확인 | Chardan Capital Markets | Neutral |
| 2019-06-14 | 재개 | Raymond James | Mkt Perform |
| 2018-11-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-30 | 개시 | SunTrust | Buy |
| 2018-02-15 | 재개 | Piper Jaffray | Overweight |
| 2017-10-12 | 개시 | Raymond James | Outperform |
모두보기
Adverum Biotechnologies Inc 주식(ADVM)의 최신 뉴스
Is Adverum Biotechnologies Inc. gaining market share2025 Valuation Update & Safe Capital Growth Plans - mfd.ru
Will Adverum Biotechnologies Inc. announce a stock splitWeekly Investment Summary & Technical Buy Zone Confirmation - mfd.ru
What is Adverum Biotechnologies Inc.’s book value per shareJuly 2025 Outlook & Reliable Trade Execution Plans - mfd.ru
Decliners Report: Can Adverum Biotechnologies Inc beat the S P 500Sell Signal & Weekly High Conviction Ideas - baoquankhu1.vn
Eli Lilly To Acquire Adverum Biotechnologies - MSN
Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biote - The National Law Review
Can Adverum Biotechnologies Inc lead its sector in growthWeekly Trend Recap & Growth Focused Stock Reports - baoquankhu1.vn
Market Recap: How do insiders feel about Adverum Biotechnologies IncPortfolio Update Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Weekly Earnings: What is Adverum Biotechnologies Inc.’s book value per share2025 AllTime Highs & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Trade Report: Is ENTO a good stock for dollar cost averagingMarket Performance Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Aug Intraday: Is Adverum Biotechnologies Inc showing insider buyingTrade Analysis Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Insider Buy: What is the earnings history of Adverum Biotechnologies IncJuly 2025 Market Mood & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug EndMonth: Is Adverum Biotechnologies Inc a strong candidate for buy and holdEarnings Overview Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
$191.2 Million Achromatopsia Market Outlook, 2026-2032, - GlobeNewswire
$191.2 Million Achromatopsia Market Outlook, 2026-2032, Featuring Adverum Biotechnologies, Homology Medicines, Mattel, REGENXBIO, Sanofi and More - Yahoo Finance
Retail Surge: What is the earnings history of Adverum Biotechnologies IncJuly 2025 Selloffs & Daily Oversold Bounce Ideas - baoquankhu1.vn
Fund Flows: Can Adverum Biotechnologies Inc stock outperform in 2025 bull marketJuly 2025 EndofMonth & Long-Term Safe Return Strategies - Bộ Nội Vụ
Wall Street Recap: Why Adverum Biotechnologies Inc stock remains undervaluedQuarterly Growth Report & Verified Short-Term Plans - Bộ Nội Vụ
Gainers Report: Why Adverum Biotechnologies Inc stock remains undervaluedMarket Risk Report & Low Risk High Reward Trade Ideas - Bộ Nội Vụ
Is Adverum Biotechnologies Inc. stock a dividend growth opportunityJuly 2025 Update & Long-Term Capital Growth Ideas - Улправда
How Adverum Biotechnologies Inc. stock benefits from strong dollarPortfolio Return Report & Real-Time Stock Entry Alerts - Улправда
Why hedge funds are buying Adverum Biotechnologies Inc. stockJuly 2025 Closing Moves & Weekly Sector Rotation Insights - Улправда
What drives Adverum Biotechnologies Inc stock priceValue Stock Picks & Capital Planning and Optimization - earlytimes.in
ADVM stock touches 52-week low at $4.01 amid market challenges - MSN
Adverum Biotechnologies, Inc. Financial Disclosures & Filings - TradingView — Track All Markets
Adverum Biotechnologies (NASDAQ:ADVM) Stock Price Passes Above 50 Day Moving Average – Time to Sell? - Defense World
Is Adverum Biotechnologies Inc. (AVU0) stock trading at attractive multiplesJuly 2025 Catalysts & Short-Term High Return Ideas - Bölüm Sonu Canavarı
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $10.50 Average PT from Brokerages - Defense World
What catalysts could drive Adverum Biotechnologies Inc. stock higherJuly 2025 Chart Watch & Fast Momentum Entry Tips - Улправда
Why Adverum Biotechnologies Inc. stock is rated strong buyWeekly Trend Report & Free Long-Term Investment Growth Plans - DonanımHaber
Why Adverum Biotechnologies Inc. stock is in analyst buy zoneJuly 2025 Market Mood & Reliable Breakout Stock Forecasts - DonanımHaber
Investor Mood: Why Adverum Biotechnologies Inc stock is in analyst buy zoneJuly 2025 Review & Precise Swing Trade Entry Alerts - moha.gov.vn
Adverum Biotechnologies releases promising phase 2 trial data - MSN
Adverum Biotechnologies Earnings Notes - Trefis
Adverum Biotechnologies, Inc. Stock ()Quote BOERSE BERLIN - marketscreener.com
Adverum Biotechnologies (NASDAQ:ADVM) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) Lowered to “Strong Sell” Rating by Wall Street Zen - Defense World
Market Catalysts: Why hedge funds are buying Adverum Biotechnologies Inc stockJuly 2025 Spike Watch & Consistent Return Investment Signals - moha.gov.vn
Hedge Fund and Insider Trading News: Cathie Wood, Michael Burry, Renaissance Technologies, Mason Capital, Millennium Management, Adverum Biotechnologies Inc (ADVM), MGM Resorts International (MGM), and More - Insider Monkey
Adverum Biotechnologies, Inc.(NasdaqCM: ADVM) dropped from S&P TMI Index - marketscreener.com
Adverum Biotechnologies completes merger and delisting - MSN
Eli Lilly completes acquisition of Adverum Biotechnologies - MSN
CEO Fischer Acquires 650,000 Of Adverum Biotechnologies Inc [ADVM] - TradingView — Track All Markets
Lilly moves forward with $3.56-per-share acquisition of Adverum - Indian Pharma Post
Lilly completes tender offer for Adverum Biotechnologies By Investing.com - Investing.com Australia
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition - The AI Journal
Lilly completes tender offer for Adverum Biotechnologies - Investing.com India
Eli Lilly (LLY) Stock on December 9, 2025: Jaypirca Breakthrough, Adverum Deal and Zepbound Price Cuts Reframe the Outlook - ts2.tech
Eli Lilly (LLY) Completes Acquisition of Adverum Biotechnologies - GuruFocus
Eli Lilly Moves Forward With Acquisition Of Adverum Biotechnologies - Nasdaq
Monday’s Insider Moves: Adverum Execs Lead Buys, Diamondback Sale Tops - Investing.com Australia
Adverum Biotechnologies Inc (ADVM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):